Raf/MEK/ERK signalling is considered to be a major RAS effector pathway, but single-agent activity for MAPK inhibitors in KRASMT CRC has shown to be ineffective [6, 7]. This evidence concerns the gene MAP2K7 and colorectal carcinoma.